Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Academic Article uri icon

Overview

MeSH Major

  • Boronic Acids
  • Lymphoma, Mantle-Cell
  • Lymphoma, Non-Hodgkin
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Pyrazines

abstract

  • Dr. O'Connor delivered the following material as a poster at the 2003 American Society of Hematology meeting highlighting results from his work with bortezomib in the treatment of non-Hodgkin's and mantle cell lymphoma. A full publication of his results will appear later this year. Abstract #2346 appears in Blood, Volume 102, issue 11, November 16, 2003. The American Society of Hematology Poster Session "Lymphoma: Treatment and Supportive Care" took place on Sunday, December 7, 2003.

publication date

  • November 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 19791425

Additional Document Info

start page

  • S21

end page

  • 2

volume

  • 2 Suppl 4